Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.52
ENZ's Cash to Debt is ranked lower than
52% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. ENZ: 3.52 )
Ranked among companies with meaningful Cash to Debt only.
ENZ' s 10-Year Cash to Debt Range
Min: 1.91  Med: 10000.00 Max: No Debt
Current: 3.52
Equity to Asset 0.58
ENZ's Equity to Asset is ranked lower than
54% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ENZ: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
ENZ' s 10-Year Equity to Asset Range
Min: 0.57  Med: 0.93 Max: 0.97
Current: 0.58
0.57
0.97
F-Score: 2
Z-Score: -2.35
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13.29
ENZ's Operating margin (%) is ranked lower than
58% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. ENZ: -13.29 )
Ranked among companies with meaningful Operating margin (%) only.
ENZ' s 10-Year Operating margin (%) Range
Min: -50.6  Med: -11.64 Max: 16.64
Current: -13.29
-50.6
16.64
Net-margin (%) -14.35
ENZ's Net-margin (%) is ranked lower than
60% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. ENZ: -14.35 )
Ranked among companies with meaningful Net-margin (%) only.
ENZ' s 10-Year Net-margin (%) Range
Min: -39.34  Med: -11.55 Max: 17.67
Current: -14.35
-39.34
17.67
ROE (%) -38.62
ENZ's ROE (%) is ranked lower than
71% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. ENZ: -38.62 )
Ranked among companies with meaningful ROE (%) only.
ENZ' s 10-Year ROE (%) Range
Min: -56.99  Med: -7.60 Max: 9
Current: -38.62
-56.99
9
ROA (%) -22.59
ENZ's ROA (%) is ranked lower than
66% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. ENZ: -22.59 )
Ranked among companies with meaningful ROA (%) only.
ENZ' s 10-Year ROA (%) Range
Min: -43.97  Med: -6.80 Max: 8.6
Current: -22.59
-43.97
8.6
ROC (Joel Greenblatt) (%) -134.25
ENZ's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. ENZ: -134.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -228.6  Med: -55.06 Max: 33.58
Current: -134.25
-228.6
33.58
Revenue Growth (3Y)(%) -5.40
ENZ's Revenue Growth (3Y)(%) is ranked lower than
73% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. ENZ: -5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENZ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -9.9  Med: 5.30 Max: 24.4
Current: -5.4
-9.9
24.4
EBITDA Growth (3Y)(%) -16.10
ENZ's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. ENZ: -16.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ENZ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 4.40 Max: 157.1
Current: -16.1
0
157.1
EPS Growth (3Y)(%) -12.20
ENZ's EPS Growth (3Y)(%) is ranked lower than
65% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ENZ: -12.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ENZ' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.6  Med: 5.40 Max: 58.7
Current: -12.2
-24.6
58.7
» ENZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ENZ Guru Trades in Q2 2014

Jim Simons 563,818 sh (+25.89%)
» More
Q3 2014

ENZ Guru Trades in Q3 2014

Dodge & Cox 15,570 sh (New)
Jim Simons 928,800 sh (+64.73%)
» More
Q4 2014

ENZ Guru Trades in Q4 2014

Jim Simons 944,337 sh (+1.67%)
Dodge & Cox Sold Out
» More
Q1 2015

ENZ Guru Trades in Q1 2015

Jim Simons 1,213,643 sh (+28.52%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.06
ENZ's P/B is ranked lower than
57% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. ENZ: 4.06 )
Ranked among companies with meaningful P/B only.
ENZ' s 10-Year P/B Range
Min: 0.85  Med: 3.00 Max: 7.13
Current: 4.06
0.85
7.13
P/S 1.39
ENZ's P/S is ranked higher than
79% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. ENZ: 1.39 )
Ranked among companies with meaningful P/S only.
ENZ' s 10-Year P/S Range
Min: 0.56  Med: 2.17 Max: 15.23
Current: 1.39
0.56
15.23
Current Ratio 1.60
ENZ's Current Ratio is ranked lower than
77% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ENZ: 1.60 )
Ranked among companies with meaningful Current Ratio only.
ENZ' s 10-Year Current Ratio Range
Min: 1.34  Med: 13.44 Max: 33.9
Current: 1.6
1.34
33.9
Quick Ratio 1.25
ENZ's Quick Ratio is ranked lower than
79% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. ENZ: 1.25 )
Ranked among companies with meaningful Quick Ratio only.
ENZ' s 10-Year Quick Ratio Range
Min: 0.95  Med: 13.06 Max: 33.15
Current: 1.25
0.95
33.15
Days Inventory 57.00
ENZ's Days Inventory is ranked higher than
60% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. ENZ: 57.00 )
Ranked among companies with meaningful Days Inventory only.
ENZ' s 10-Year Days Inventory Range
Min: 35.73  Med: 59.02 Max: 117.91
Current: 57
35.73
117.91
Days Sales Outstanding 43.78
ENZ's Days Sales Outstanding is ranked higher than
78% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. ENZ: 43.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZ' s 10-Year Days Sales Outstanding Range
Min: 47.44  Med: 111.98 Max: 177.79
Current: 43.78
47.44
177.79

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 12.00
ENZ's Price/Net Current Asset Value is ranked lower than
66% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.30 vs. ENZ: 12.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZ' s 10-Year Price/Net Current Asset Value Range
Min: 2.37  Med: 5.79 Max: 33.58
Current: 12
2.37
33.58
Price/Tangible Book 6.98
ENZ's Price/Tangible Book is ranked lower than
68% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.26 vs. ENZ: 6.98 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZ' s 10-Year Price/Tangible Book Range
Min: 1.97  Med: 5.24 Max: 29.77
Current: 6.98
1.97
29.77
Price/Median PS Value 0.64
ENZ's Price/Median PS Value is ranked higher than
83% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. ENZ: 0.64 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZ' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 3.86 Max: 22.21
Current: 0.64
0.26
22.21
Earnings Yield (Greenblatt) (%) -10.77
ENZ's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ENZ: -10.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZ' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -13.7  Med: 0.00 Max: 0
Current: -10.77
-13.7
0
Forward Rate of Return (Yacktman) (%) 7.53
ENZ's Forward Rate of Return (Yacktman) (%) is ranked lower than
58% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.12 vs. ENZ: 7.53 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENZ' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -31.2  Med: -1.20 Max: 16.7
Current: 7.53
-31.2
16.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, IDXX » details
Traded in other countries:EZB.Germany,
Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Companys technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services to the health care community in the New York Metropolitan and New Jersey areas. The Company operates in three segments of which the Therapeutics and Life Sciences segments have evolved out of its core competencies. enzo Life Sciences manufactures, develops and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers world-wide and has amassed a large patent and technology portfolio, enzo Clinical Labs is a regional clinical laboratory serving the New York Metropolitan and New Jersey areas, enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of enzo Life Sciences. The Company has developed a portfolio of proprietary technologies with research, diagnostic and therapeutic applications. It is applying its core technologies to develop novel therapeutics as well as research tools for the life sciences and clinical diagnostics markets. In addition, The Company provides clinical laboratory services to physicians and other health care providers in the New York Metropolitan and New Jersey area. The Company is organized to the development, production, marketing and sales of life science research reagents. The products supplied by Enzo Life Sciences include small molecules, proteins, antibodies, peptides, assay kits and custom services. Enzo Life Sciences is organized to promote and market its product through its seven brands Enzo, Alexis, Apotech, Axxora, Biomol, Assay Designs and Stressgen. Therapeutic Development Programs include Autoimmune Uveitis, Inflammatory bowel diseases. Osteoporosis (and certain bone disorders) and Diabetes, Non-Alcoholic SteatoHepatitis (NASH) and Human Immunodeficiency Virus (HIV-1). The Company competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The clinical laboratory industry is subject to federal and state regulation, including inspections and audits by governmental agencies.
» More Articles for NYSE:ENZ

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 24 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 
Enzo Biochem Inc. (ENZ) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
ENZO Biochem Reaches Patent Infringement Settlement - PRESS RELEASE Jul 22 2015
ENZO Biochem Reaches Patent Infringement Settlement Jul 22 2015
Enzo Biochem Reaches Patent Infringement Settlement Jul 22 2015
ENZO BIOCHEM INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 22 2015
Enzo Biochem Reports Favorable Delaware Court Markman Hearing Ruling Jul 08 2015
Enzo Biochem Reports Favorable Delaware Court Markman Hearing Ruling Jul 08 2015
ENZO BIOCHEM INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 07 2015
Enzo Biochem to Present at Cantor Fitzgerald Healthcare Conference Jul 06 2015
Enzo Biochem to Present at Cantor Fitzgerald Healthcare Conference Jul 06 2015
Enzo Biochem Reaches $7.1 Million Patent Infringement Settlement with Luminex Corporation Jul 06 2015
Enzo Biochem Reaches $7.1 Million Patent Infringement Settlement with Luminex Corporation Jul 06 2015
Edited Transcript of ENZ earnings conference call or presentation 10-Jun-15 12:30pm GMT Jun 16 2015
ENZO BIOCHEM INC Financials Jun 13 2015
10-Q for Enzo Biochem, Inc. Jun 11 2015
ENZO Biochem Reports Third Quarter Results, Including Strong Revenue Growth at Clinical Labs... Jun 09 2015
Enzo Biochem reports 3Q loss Jun 09 2015
Enzo Biochem reports 3Q loss Jun 09 2015
ENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jun 09 2015
Enzo Biochem Reports Third Quarter Results, Including Strong Revenue Growth at Clinical Labs... Jun 09 2015
Q3 2015 Enzo Biochem Inc Earnings Release - After Market Close Jun 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK